5 companies filing this week (30 Nov - 04 Dec)

---

17 Education & Technology Group (YQ) [2011]

Software & Tech Services | 27,400,000 shares | $9.50 - $11.50 | Nasdaq

17 Education & Technology Group Inc. operates as a education technology company. The Company offers data-driven teaching, learning, and assessment products to teachers, students, and parents with online tutoring courses and in-school classroom solutions. 17 Education & Technology Group serves customers in China.

Website | SEC report | Bloomberg

> Notify me when $YQ goes public

Kinnate Biopharma (KNTE) [2018]

Health Care | 10,000,000 shares | $16.00 - $18.00 | Nasdaq

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations.

Website | SEC report | Bloomberg | Crunchbase

> Notify me when $KNTE goes public

Seer (SEER) [2017]

Health Care | 8,825,000 shares | $16.00 - $18.00 | Nasdaq

Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company’s platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurologicaldiseases, drive earlier treatment and improve patient outcomes.

Website | SEC report | Bloomberg | Crunchbase

> Notify me when $SEER goes public

Sigilon Therapeutics (SGTX) [2015]

Health Care | 5,600,000 shares | $17.00 - $19.00 | Nasdaq

Sigilon Therapeutics is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.

Website | SEC report | Bloomberg | Crunchbase

> Notify me when $SGTX goes public

Silverback Therapeutics (SBTX) [2016]

Health Care | 6,950,000 shares | $17.00 - $19.00 | Nasdaq

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible.

Website | SEC report | Bloomberg | Crunchbase

> Notify me when $SBTX goes public